DALLAS, Dec. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access' partner, SpePharm, in six European countries, including the UK, Germany, Italy, Norway, Greece and Sweden. Access is conducting pre-marketing activities, including ramping of commercial production, with the goal of a commercial launch in 1H 2010 in the US. MuGard was granted the CE mark certification in Europe in late 2008 with the labeling "prevention and management of the lesions and symptoms of oral mucositis." Key findings and feedback from SpePharm's ongoing commercial launch and patient assessment project include:
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved